In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain ...

This research roundup discusses the newfound relationship between the Shingles vaccine and dementia, a gene responsible for arterial development and the role of glucose as a master regulator in our ...

Researchers have uncovered a surprising mechanism by which a single genetic mutation in the BCL11B gene causes both immune dysfunction and brain development issues.

Researchers have uncovered the critical role of the "fuzzy coat" of α-synuclein in forming Lewy bodies associated with ...

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...

Continued treatment with AXS-05, a combination of dextromethorphan and bupropion, significantly reduces the risk for recurrence of Alzheimer’s disease–related agitation, phase 3 results show.

Bilingualism offers more than just the ability to navigate multiple languages—it also has a profound impact on brain health. Research has increasingly shown ...

Agitated patients are often prescribed antipsychotic medications and sedatives off-label, but this can pose a risk to the ...

Blarcamesine is a sigma 1 receptor agonist which targets Alzheimer's pathology upstream of amyloid and tau pathology.

Damage to the genetic material of mitochondria—the mitochondrial DNA or mtDNA for short—can lead to diseases such as ...

Research reveals how specific sleep stages protect brain vulnerable to Alzheimer's, offering hope through simple lifestyle ...

Hoth Therapeutics (HOTH) announced groundbreaking preclinical data supporting the therapeutic potential of its lead Alzheimer’s candidate, ...